TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation

NARecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

April 23, 2025

Primary Completion Date

May 1, 2028

Study Completion Date

February 2, 2031

Conditions
InfectionCancerRejectionKidney Transplantation
Interventions
BIOLOGICAL

TTV DNAemia

Every 3 months, one sample added at the same time (7mL) of a routine laboratory analysis for TTV DNAemia

OTHER

EQ-5D-5L questionnaire

Completed every 6 months and each time a complication of interest occurs

BIOLOGICAL

Biological tests

Biological tests as routine care procedure (creatinine, CNI pre-dose trough level) will be performed every 6 months

Trial Locations (4)

31059

NOT_YET_RECRUITING

Département de Néphrologie et Transplantation d'Organes Hôpital Rangueil - CHU de Toulouse, Toulouse (France)

33000

NOT_YET_RECRUITING

Service de Néphrologie-Transplantation-Dialyse I Hôpital Pellegrin I - CHU Bordeaux, Bordeaux (France)

67091

NOT_YET_RECRUITING

Service de Néphrologie, Dialyse et Transplantation Rénale Nouvel Hôpital Civil, Strasbourg (france)

69003

RECRUITING

Service de transplantation, néphrologie et immunologie clinique Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

BioMérieux

INDUSTRY

lead

Hospices Civils de Lyon

OTHER

NCT06829719 - TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation | Biotech Hunter | Biotech Hunter